Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1526445 | 0.85 | KIF11 (0.57) | KIF11SIRT2 | |
| SCHEMBL10315743 | 0.83 | KIF11 (0.47) | KIF11SIRT2 | |
| SCHEMBL9972416 | 0.79 | KIF11 (0.46) | KIF11SIRT2 | |
| SCHEMBL98808 | 0.79 | KIF11 (0.53) | KIF11SIRT2 | |
| SCHEMBL18176011 | 0.77 | KIF11 (0.52) | KIF11 | |
| SCHEMBL6909006 | 0.77 | KIF11 (0.55) | KIF11 | |
| SCHEMBL8447104 | 0.77 | KIF11 (0.55) | KIF11 | |
| SCHEMBL21093254 | 0.77 | KIF11 (0.55) | KIF11 | |
| SCHEMBL5357811 | 0.77 | KIF11 (0.55) | KIF11 | |
| SCHEMBL7796199 | 0.77 | KIF11 (0.55) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127797-A1 | PRODRUG COMPRISING A DRUG-LINKER CONJUGATE | ASCENDIS PHARMA A/S (DK) | 2025-04-24 | — | — | US | disclosed |
| US-20240041897-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA GMBH (DE) | 2024-02-08 | — | — | US | disclosed |
| US-20220331334-A1 | Prodrug Comprising a Drug-Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2022-10-20 | — | — | US | disclosed |
| EP-3981761-A2 | INTERMEDIATES FOR PRODRUGS | Ascendis Pharma A/S (DK) | 2022-04-13 | — | — | EP | disclosed |
| EP-2596805-B1 | Prodrug comprising a drug-linker conjugate | ASCENDIS PHARMA AS (DK) | 2021-10-27 | — | — | EP | disclosed |
| US-20200046725-A1 | Prodrug Comprising a Drug Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2020-02-13 | — | — | US | disclosed |
| EP-2237799-B1 | PRODRUG COMPRISING A SELF-CLEAVABLE LINKER | ASCENDIS PHARMA AS (DK) | 2019-04-10 | — | — | EP | disclosed |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2017-04-13 | — | — | US | disclosed |
| US-20150057221-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2015-02-26 | — | — | US | disclosed |
| US-8906847-B2 | Prodrug comprising a drug linker conjugate | ASCENDIS PHARMA A/S (DK) | 2014-12-09 | — | — | US | disclosed |
| CN-101980725-B | Prodrug comprising a drug linker conjugate | ASCENDIS PHARMA AS | 2013-06-12 | — | — | CN | disclosed |
| EP-2596805-A1 | Prodrug comprising a drug linker conjugate | Ascendis Pharma A/S (DK) | 2013-05-29 | — | — | EP | disclosed |
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2011-03-03 | — | — | US | disclosed |
| CN-101980725-A | Prodrug comprising a drug linker conjugate | ASCENDIS PHARMA AS | 2011-02-23 | — | — | CN | disclosed |
| EP-2237799-A2 | PRODRUG COMPRISING A SELF-CLEAVABLE LINKER | Ascendis Pharma AS (DK) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009095479-A2 | PRODRUG COMPRISING A SELF-CLEAVABLE LINKER | ASCENDIS PHARMA AS (DK) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057221-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | KIF11 3253/4885SIRT2 1025/4885 |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | H1-0, H1-3, H1-2 | KIF11 3253/4885SIRT2 1025/4885 |
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | KIF11 3244/4885SIRT2 1034/4885 |
| US-20200046725-A1 | Prodrug Comprising a Drug Linker Conjugate | H1-0, H1-3, H1-2 | KIF11 3221/4885SIRT2 1043/4885 |
| US-20240041897-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | KIF11 3253/4885SIRT2 1025/4885 |
| US-20220331334-A1 | Prodrug Comprising a Drug-Linker Conjugate | H1-0, H1-3, DLST | KIF11 3239/4885SIRT2 1024/4885 |
| US-20250127797-A1 | PRODRUG COMPRISING A DRUG-LINKER CONJUGATE | H1-0, H1-3, DLST | KIF11 3239/4885SIRT2 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.